Health Care • Ophthalmic Goods
$60.34 ▲ +0.93
(+1.57%)
MKT CAP: $11.47B • VOL: 1.76M
52W L $51 52W H $90
COO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-10-31 | FY 2024
FILED 2024-10-31 | FY 2023
FILED 2023-10-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.09B | $3.90B | $3.59B |
| YoY Revenue Growth % | +5.1% | +8.4% | — |
| Gross Profit | $2.68B | $2.60B | $1.58B |
| Gross Margin % | 65.5% | 66.6% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $682.9M | $705.7M | $533.1M |
| Operating Margin % | 16.7% | 18.1% | 14.8% |
| Net Income (GAAP) | $374.9M | $392.3M | $294.2M |
| EBITDA (Normalized) | $972.8M | $1.04B | $662.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $796.1M | $709.3M | $607.5M |
| Capital Expenditures (CapEx) | $362.4M | $421.2M | $161.7M |
| Free Cash Flow (FCF) | $433.7M | $288.1M | $445.8M |
| FCF Margin % | 10.6% | 7.4% | 12.4% |
| Return on Invested Capital (ROIC %) | 5.3% | 5.3% | 11.0% |
| Cash & Short-Term Equivalents | $124.9M | $100.9M | $694.2M |
| Total Debt (Short + Long Term) | $1.88B | $2.49B | $1.48B |
| Total Stockholders' Equity | $8.36B | $8.13B | $3.03B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR COO.